Literature DB >> 12626985

Free radical and drug oxidation products in an intensive care unit sedative: propofol with sulfite.

Max T Baker1, Marc S Gregerson, Sean M Martin, Garry R Buettner.   

Abstract

OBJECTIVES: Some propofol emulsion formulations contain EDTA or sodium metabisulfite to inhibit microbe growth on extrinsic contamination. EDTA is not known to react with propofol formulation components; however, sulfite has been shown to support some oxidation processes and may react with propofol. This study compared the oxidation of propofol and the formation of free radicals by electron paramagnetic resonance analysis in EDTA and sulfite propofol emulsions during a simulated intensive care unit 12-hr intravenous infusion.
DESIGN: Controlled laboratory study.
SETTING: University laboratory.
MEASUREMENTS AND MAIN RESULTS: Propofol emulsions (3.5 mL) were dripped from spiked 50-mL vials at each hour for 12 hrs. Two propofol oxidation products, identified as propofol dimer and propofol dimer quinone, were detected in sulfite and EDTA propofol emulsions; however, sulfite propofol emulsion contained higher quantities of both compounds. After initiation of the simulated infusion, the quantities of propofol dimer and propofol dimer quinone increased in the sulfite propofol emulsion, but the lower levels in the EDTA propofol emulsion remained constant. Sulfite propofol emulsion began to visibly yellow at about 6-7 hrs. The EDTA propofol emulsion remained white at all times. The absorbance spectra of the propofol dimer and propofol dimer quinone extracted from sulfite propofol emulsion showed that propofol dimer did not absorb in the visible spectrum, but the propofol dimer quinone had an absorbance peak at 421 nm, causing it to appear yellow. Electron paramagnetic resonance analysis of the propofol emulsion containing metabisulfite revealed that the sulfite propofol emulsion yielded a strong free radical signal consistent with the formation of the sulfite anion radical (SO3*-). The EDTA propofol emulsion yielded no free radical signal above background.
CONCLUSION: Sulfite from the metabisulfite additive in propofol emulsion creates an oxidative environment when these emulsions are exposed to air during a simulated intravenous infusion. This oxidation results in propofol dimerization and emulsion yellowing, the latter of which is caused by the formation of propofol dimer quinone. These processes can be attributed to the rapid formation of the reactive sulfite free radical.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626985     DOI: 10.1097/01.CCM.0000053560.05156.73

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

Review 1.  Propofol: a review of its role in pediatric anesthesia and sedation.

Authors:  Vidya Chidambaran; Andrew Costandi; Ajay D'Mello
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

2.  Propofol emulsion-free drug concentration is similar between batches and stable over time.

Authors:  Robert Damitz; Anuj Chauhan; Nikolaus Gravenstein
Journal:  Rom J Anaesth Intensive Care       Date:  2016-04

3.  A novel, lipid-free nanodispersion formulation of propofol and its characterization.

Authors:  Hongming Chen; Zhong Zhang; Orn Almarsson; Jean-Francois Marier; Dina Berkovitz; Colin R Gardner
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

Review 4.  Clinical physiology and mechanism of dizocilpine (MK-801): electron transfer, radicals, redox metabolites and bioactivity.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

5.  Physical compatibility of MCT/LCT propofol emulsions with crystalloids during simulated Y-site administration.

Authors:  Gábor Szalai; Gábor Katona; Mária Matuz; Orsolya Jójárt-Laczkovich; Péter Doró
Journal:  Eur J Hosp Pharm       Date:  2018-01-18

6.  In vitro evaluation of the potential role of sulfite radical in morphine-associated histamine release.

Authors:  Emma M Gordon; Carolyn Myers; Jeffrey Blumer
Journal:  BMC Pharmacol       Date:  2004-10-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.